The publisher explores Teva’s prescription pharmaceutical performance and outlook over 2019–29.
Snapshot
Model updates (7 May 2020)
Model updates (12 February 2020)
Model updates (11 November 2019)
Model updates (8 August 2019)
Snapshot
- Overview: Teva will look to build on the launches of Austedo and Ajovy to counter the erosion of Copaxone, the litigation risk around opioids in the US, and the company’s high debt burden.
- Key themes: [1] Launch of Austedo is going extremely well, with favorable national formulary coverage and growth in Huntington’s disease, chorea, and tardive dyskinesia [2] Teva’s North American generics business will remain broadly stable over the forecast period [3] Copaxone sales will continue to fall as generics erode its market share.
Model updates (7 May 2020)
- Treanda/Bendeka forecast adjusted higher due to patent resolution extending exclusivity until 2031
- Ajovy forecast adjusted lower
- Biosimilars forecast adjusted higher due to launches of Truxima and Herzuma.
Model updates (12 February 2020)
- Copaxone forecast adjusted higher as pace of generic decline starts to abate
- Austedo forecast adjusted higher due to continued adoption
Model updates (11 November 2019)
- Copaxone forecast adjusted higher due to near-term stabilization in US revenues
- Ajovy forecast adjusted lower due to competition in the CGRP market
- Bendeka/Treanda forecast adjusted lower due to generic competition
- Biosimilars forecast adjusted lower due to launch timing of Truxima and Herzuma.
Model updates (8 August 2019)
- Austedo forecast adjusted higher due to continued strong launch
- Ajovy forecast adjusted lower due to weaker than expected launch in the US
- Copaxone forecast adjusted lower due to continued generic erosion in the US
- Fasinumab forecast added.
Table of Contents
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview
